Several researchers from Boston-based Dana-Farber Cancer Institute joined San Francisco-based Parker Institute for Cancer Immunotherapy earlier this month, Market Insider reports.
Dana-Farber researchers will engage in a variety of projects in line with the Parker Institute's goals.
As part of the Parker Institute, Dana-Farber researchers will have access to several innovative tools and resources, including clinical trial management, bioinformatics and data analysis, and intellectual property management to drive research efforts.
The four Dana-Farber physicians joining the Parker Institute are:
- Dr. W. Nicholas Haining
- Catherine J. Wu, MD
- Philip Kranzusch, PhD
- F. Stephen Hodi, Jr., MD
"The best way to make a huge impact in the field of oncology is to work collaboratively with leading researchers and institutions. [The partnership] will help us overcome barriers that stand in the way of developing revolutionary therapies," said Laurie H. Glimcher, MD, president and CEO of Dana-Farber Cancer Institute. "Dana-Farber is continuing to advance the rapid progress seen in immuno-oncology over the past five to 10 years, and we are honored to be part of the impressive team that the Parker Institute has convened. We are hopeful that with so many talented scientists working in unison toward a common goal, we will have many positive outcomes."